Neuroprotective effects of L-Dopa-modified zinc oxide nanoparticles on the rat model of 6-OHDA-ınduced Parkinson's disease

Basit Öğe Kaydı
dc.contributor.authorYeni, Yesim
dc.contributor.authorGenc, Sidika
dc.contributor.authorErtugrul, Muhammed Sait
dc.contributor.authorNadaroglu, Hayrunnisa
dc.contributor.authorGezer, Arzu
dc.contributor.authorMendil, Ali Sefa
dc.contributor.authorHacimuftuoglu, Ahmet
dc.date.accessioned2026-06-19T06:39:36Z
dc.date.available2026-06-19T06:39:36Z
dc.date.issued2024
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractParkinson's disease (PD) is a chronic neurodegenerative case. As the disease progresses, the response time to doses of levodopa (L-Dopa) becomes shorter and the effects of the drug are severely limited by some undesirable side effects such as the 'on-off' phenomenon. In several diseases, including Parkinson's, nanoparticles can deliver antioxidant compounds that reduce oxidative stress. This study evaluates and compares the neuroprotective effects of L-Dopa-modified zinc nanoparticles (ZnNPs) in the 6-hydroxydopamine (6-OHDA)-induced PD rat model. For this purpose, the synthesis of NPs was carried out. Scanning electron microscopy, X-ray diffraction and Fourier transform infrared spectrophotometer were used for characterization. The rats were randomized into 9 experimental groups: control, lesion group (6-OHDA), 6-OHDA + 5 mg/kg L-Dopa, 6-OHDA + 10 mg/kg L-Dopa, 6-OHDA + 20 mg/kg L-Dopa, 6-OHDA + 20 mg/kg ZnNPs, 6-OHDA + 40 mg/kg ZnNPs, 6-OHDA + 30 mg/kg ZnNPs + L-Dopa, and 6-OHDA + 60 mg/kg ZnNPs + L-Dopa. Behavioral tests were performed on all groups 14 days after treatment. Phosphatase and tensin homolog, Excitatory amino acid transporter 1/2, and Glutamine synthetase gene analyses were performed on brain samples taken immediately after the tests. In addition, histological and immunohistochemical methods were used to determine the general structure and properties of the tissues. We obtained important findings that L-Dopa-modified ZnNPs increased the activity of glutamate transporters. Our experiment showed that glutamate increases neuronal cell vitality and improves behavioral performance. Therefore, L-Dopa-modified ZnNPs can be used to prevent neurotoxicity. According to what we found, results show that L-Dopa-modified ZnNPs will lend to the effective avoidance and therapy of PD.
dc.description.sponsorshipTrkiye Bilimsel ve Teknolojik Arascedil;timath;rma Kurumu
dc.description.sponsorshipNo Statement Available
dc.identifier.doi10.1038/s41598-024-69324-4
dc.identifier.issn2045-2322
dc.identifier.issue1
dc.identifier.orcid0000-0002-6719-7077
dc.identifier.orcid0000-0002-7885-5645
dc.identifier.pmid39154054
dc.identifier.scopus2-s2.0-85201431716
dc.identifier.scopusqualityN/A
dc.identifier.urihttps://doi.org/10.1038/s41598-024-69324-4
dc.identifier.urihttps://hdl.handle.net/20.500.12899/5703
dc.identifier.volume14
dc.identifier.wosWOS:001292901700012
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherNature Portfolio
dc.relation.ispartofScientific Reports
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20260612
dc.subject6-Ohda
dc.subjectEaat 1/2
dc.subjectGlul
dc.subjectL-Dopa
dc.subjectPten
dc.subjectZnnp
dc.titleNeuroprotective effects of L-Dopa-modified zinc oxide nanoparticles on the rat model of 6-OHDA-ınduced Parkinson's disease
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu